Clinical Identification and Characteristic Analysis of Giant Cell Myocarditis in 12 Cases
Shangyu Liu1, Lihui Zheng1, Lishui Shen1
1State Key Laboratory of Cardiovascular Disease, National Center for Cardiovascular Diseases, Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Insights
Giant cell myocarditis (GCM) is often misdiagnosed. Early diagnosis via endomyocardial biopsy improves outcomes for this rare, aggressive heart condition.
Area of Science:
- Cardiology
- Pathology
Background:
- Giant cell myocarditis (GCM) is a rare and aggressive cardiomyopathy with high mortality.
- Prompt diagnosis and treatment are crucial for managing GCM.
Purpose of the Study:
- To analyze the clinical manifestations and progression of patients with Giant cell myocarditis.
- To evaluate diagnostic delays and accuracy in GCM cases.
Main Methods:
- Retrospective analysis of 12 patients diagnosed with GCM via endomyocardial biopsy (EMB) or during heart transplantation (HTx).
- Collected data included demographics, cardiac function, arrhythmias, and preliminary diagnoses.
- Compared diagnostic timelines and cardiac damage between EMB and HTx diagnosis groups.
Main Results:
- GCM was frequently misdiagnosed initially as other cardiomyopathies or myocarditis.
- Patients diagnosed via EMB had shorter symptom-onset-to-diagnosis times (6.6 months) and better left ventricular ejection fraction (47.2%) compared to HTx diagnoses (11.0 months, 31.4%).
Conclusions:
- Pathological examination of myocardial tissue is essential for accurate GCM diagnosis.
- Endomyocardial biopsy enables earlier identification of GCM, potentially improving patient outcomes.
Abstract:
Aims: Giant cell myocarditis (GCM) is a rare, rapidly progressing cardiomyopathy with high mortality, if not diagnosed and treated in time. We analyzed the progression and clinical manifestations of patients with definitive diagnosis of GCM. Methods and Result: We enrolled 12 patients diagnosed with GCM in the explanted heart during heart transplantation (HTx) or by endomyocardial biopsy (EMB) and collected information on demographic data, cardiac structure and function, arrhythmias, preliminary diagnosis, and delay of the diagnosis. Seven cases were diagnosed from biopsy samples during HTx, and five cases were diagnosed through EMB. Before the diagnosis of GCM based on pathological analysis, these patients had been incorrectly diagnosed with arrhythmogenic right ventricular cardiomyopathy (n = 5), dilated cardiomyopathy (n = 2), ventricular tachycardia (n = 2), viral myocarditis (n = 1), cardiac amyloidosis (n = 1), and ischemic cardiomyopathy (n = 1) based on clues such as symptoms, arrhythmia, and cardiac imaging. Patients diagnosed with GCM through EMB had a shorter symptom-onset-to-diagnosis time (6.6 ± 2.7 months) and milder heart damage (left ventricular ejection fraction, 47.2 ± 8.8%) than those diagnosed during HTx (11.0 ± 3.3 months, P = 0.034; 31.4 ± 10.9%, P = 0.024). Conclusion: GCM is easily misdiagnosed as other types of myocarditis and cardiomyopathy. Pathological examination of the myocardium is the most reliable diagnostic method for GCM. Endocardial biopsy can identify patients with GCM at an earlier stage.
More Related Videos
Related Concept Videos
Myocarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Myocarditis I: Introduction
Pericarditis II: Clinical Features and Diagnostic Tests
Cardiomyopathy II: Dilated Cardiomyopathy
Myocarditis III: Medical Management


